Scinopharm Taiwan, Ltd.

YuanChang Huang

MengFen Ho

Julian Paul Henschke

Tsung-Cheng Hu

Wei-Shuo Lo

TsungYu Hsiao

Tsung-Yu Hsiao

Wen-Wei Lin

Ming-Chih Wu

Yu-Sheng Lin

Hsiao-ping Fang

HsinChang Tseng

WenShing Tsao

Kuan Hsun Wang

Crystalline form S1 of lifitegrast characterized by a powder X-ray diffraction pattern with peaks at about 10.7&#xb1;0.2, 16.2&#xb1;0.2, 19.9&#xb1;0.2, 22.1&#xb1;0.2, 24.7&#xb1;0.2, and 25.9&#xb1;0.2 degrees two-theta, crystalline form S2 of lifitegrast characterized by a powder X-ray diffraction pattern with peaks at about 16.4&#xb1;0.2, 24.9&#xb1;0.2, and 26.2&#xb1;0.2 degrees two-theta, and processes of making thereof are provided.

Crystal forms of lifitegrast

The present invention provides efficient, economical, and improved methods for synthesizing ibrutinib and intermediates thereof. The invention involves a unique biphasic acylation reaction system which advantageously allows for easy separation of ibrutinib from the reaction mixture without additional extraction and wash steps. The isolated ibrutinib formed using the methods described herein can be useful in the preparation of an amorphous form of ibrutinib. In some embodiments, the isolated ibrutinib produced by the processes described herein is a homogenous solution of ibrutinib and DMSO which may be directly used in the formation of the amorphous polymorph. In some embodiments, the isolated ibrutinib is solid ibrutinib. The solid ibrutinib may also be used in the formation of amorphous ibrutinib.

Process for preparing ibrutinib and its intermediates

The present invention provides novel crystalline forms of apremilast hemitoluene solvate, apremilast hydrate, and apremilast anhydrate and an amorphous form of apremilast, and processes for the preparation of these forms.

Forms of apremilast and the process of making the same

The present invention provides crystalline forms, including an anhydrate form, of cabazitaxel and processes for the preparation of these forms, designated as Forms C1, C2, C3, C4, C5, C6, C7, C8, C8b, C9 and C9p.

Crystalline forms of cabazitaxel

The present invention provides crystalline forms, including an anhydrate form, of cabazitaxel and processes for the preparation of these forms, designated as Forms C1, C2, C3, C4, C5, C6, C7, C8, C8, C9 and C9

Growing community of inventors

Kaohsiung, Taiwan

YuanChang Huang